PMV's $50.8M financing creates supply, not a clean short

Summary: U.S. short Watchlist, reject for current execution. PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) was quoted at $1.2600 in a live market-data snapshot at 2026-09-02 15:18:57 UTC, down 2.32558%, with an intraday range of $1.2450 to $1.2900, an open of $1.2600, 245,195 shares of volume, and a provider market-cap field of $67.268 million. A second real-time page showed $1.2750 at 11:34 a.m. Eastern Time, so the quote window must remain explicit. PMV priced a registered underwritten offering on August 31 that combines 22.055 million common shares or 19.900 million pre-funded warrants with 41.955 million immediately exercisable common warrants, at $1.21 per common share and accompanying warrant or $1.20999 per pre-funded warrant and accompanying warrant. The filing expected delivery on or about September 2, subject to customary conditions; a closing and settlement record was not verified in this run. The June 30 Form 10-Q reports $79.431 million of cash, cash equivalents, and marketable securities, $34.256 million of first-half operating cash use, no product revenue, and substantial doubt about continuing as a going concern. PMV's August 31 interim update reported a 46% overall response rate in 76 evaluable ovarian-cancer patients, a 10.0-month median duration of response, FDA feedback supporting an accelerated-approval strategy, and an NDA plan for the first quarter of 2027. The specific disagreement is between a simple dilution short and a company that is simultaneously buying runway and carrying a live clinical catalyst. The common and pre-funded portion equals about 78.5% of the June 30 common denominator, while the accompanying warrants add another conditional 78.5%. The reference-only base decline clears 10%, but a clinical or regulatory squeeze to $2.05 is a credible 62.7% adverse move. The gross base-to-adverse ratio is only 0.39:1. Keep entry.price null and execution.can_execute false. This is research, not personalized financial advice.

Run timestamp: 2026-09-02T23:37:39+08:00 (Asia/Singapore). Quote timestamps, filing dates, settlement state, catalyst windows, and publication time are separate.

Opportunity Ranking

Rank	Candidate	Direction	Mispricing	Evidence Freshness	Catalyst Window	Positioning	10/5 Status	Tradeability	Main Rejection Risk
1	PMV Pharmaceuticals (PMVP)	Short	A same-day offering creates a large conditional common-equivalent supply block at $1.21, but the company receives roughly $47M net and carries promising Phase 2 data, so the dilution narrative is incomplete	Aug. 31 pricing and data filings, Sep. 2 live quote	Sep. 2 expected delivery, first post-close tape, Q4 2026 data update, Q1 2027 NDA plan	Public borrow about 1.2%, 3.2M available; 2.2M short, 4.2% of shares, 5.9 days to cover	Watchlist; reject	245K live volume and large registered market, but settlement, bid, ask, spread, depth, and exit quality are unverified	$79M existing financial assets, $47M new net proceeds, positive data, or FDA progress can overpower the supply overhang
2	KALA BIO (KALA)	Short	A $0.229M cash balance, a $7M callable note receivable, and a recent Nasdaq deficiency compete with a post-split quote and a strategic AI-infrastructure narrative	Aug. 27 8-K, June 30 10-Q, Sep. 2 live quote	Nasdaq appeal, note collection, financing, and next filing	Public borrow about 8.07%, 35K available; July 31 short interest about 280K	Reject	255K live volume, but one market-cap field and the post-split denominator are not reconciled	The prior August screen already used KALA as an alternative, and current quote, claims, and exchange state remain too unstable for a new selection
3	LivePerson (LPSN)	Short	A September 2 merger vote creates a binary break risk, but more than 97% of votes cast were reported in favor and the transaction is tentatively scheduled to close before September 4	Aug. 20 vote update, June 30 10-Q, Sep. 2 vote window	Sep. 2 shareholder vote, Sep. 3 last trading date, Sep. 4 tentative close	Public borrow about 2.5%, 661K short, 1.8 days to cover	Reject	92.5K live volume; deal consideration and SoundHound VWAP remain moving	Approval, a quorum, and a closing path create a much larger adverse risk than the vote-failure downside

The screen used mechanism-specific searches combining 'priced underwritten offering pre-funded warrant regulatory reset NDA acceptance', 'Nasdaq deficiency appeal cash note receivable post-split quote', and 'merger vote quorum last trading date cash adjustment VWAP collar'. Generic earnings-only searches were not used. The repository scan found no dedicated PMVP article or PMVP signal. FFAI, SWRD, FTCI, SNGX, and KALA financing or reverse-split theses were not selected because they are already covered as dedicated articles or recent alternatives with materially overlapping mechanisms. The selected PMVP thesis is a new offering-settlement and regulatory-warrant-reset state.

Selected opportunity: PMV Pharmaceuticals common stock, Nasdaq Global Select Market.

Why this one now: PMVP has the cleanest new event boundary. A priced offering is public, but delivery and settlement are still separate. The current price is close to the package price, the common denominator can expand sharply, and the warrant terms contain a later regulatory reset. At the same time, the company has real cash, a large upcoming financing receipt, and a clinical data path that can move the stock higher. That tension is more decision-useful than a simple dilution headline.

What should surprise the reader: The same FDA acceptance event that could support the common price can also reduce the warrant exercise price and increase the number of warrant shares. The offering is therefore not one directional supply. It is a conditional capital-structure option with a positive regulatory trigger.

Why This Is the Best Opportunity Right Now

The August 31 Form 8-K documents a priced offering expected to close on September 2, subject to customary closing conditions. It covers 22,055,000 common shares, or pre-funded warrants for up to 19,900,000 shares for certain investors, plus common warrants for up to 41,955,000 shares. Each common share or pre-funded warrant is paired with one common warrant. The package price is $1.21 for a common share and warrant, or $1.20999 for a pre-funded warrant and warrant. The common warrants are immediately exercisable, initially at $1.21, and expire five years after issuance. PMV Pharmaceuticals August 31, 2026 Form 8-K

The offering is large relative to the existing denominator. PMV's June 30 10-Q reports 53,460,432 common shares issued and outstanding. The common and pre-funded portion of the new offering represents 41.955 million common-equivalent shares, or approximately 78.5% of that current denominator. The accompanying 41.955 million warrants represent another approximately 78.5% of the same denominator if exercised. This is stress arithmetic, not current float. Pre-funded warrants are conditional claims until exercised, and common warrants are not current shares.

The filing's final economics are more complicated than the headline. The public prospectus reports $50.765 million of gross offering proceeds, $3.046 million of underwriting discounts and commissions, and $47.719 million of proceeds before other expenses. The August 31 8-K estimates approximately $47.0 million of net proceeds after discounts, commissions, and estimated offering expenses. Both primary sources agree on a substantial cash injection, but the final cash receipt, delivered securities, and post-close denominator were not independently verified in this run. PMV Pharmaceuticals September 2, 2026 Form 424B5

That cash matters. As of June 30, PMV held $79.431 million of cash, cash equivalents, and marketable securities, had used $34.256 million of operating cash in the first half, and had no product revenue. Management said the available financial assets might not fund the planned operation for at least one year and disclosed substantial doubt about going concern. The same filing says the company plans to fund operations through additional public or private equity, convertible or debt financing, strategic collaborations, licensing, or other sources. PMV Pharmaceuticals June 30, 2026 Form 10-Q

The new offering changes that runway. The August 31 8-K says PMV expects the offering proceeds, together with existing cash and cash equivalents, to fund operating expenses and capital expenditure requirements into the first quarter of 2028, excluding any underwriters' option. This is management guidance, not a cash guarantee. It is nevertheless a serious counterparty fact against a near-term financing-failure short.

The clinical catalyst is also real, but not settled. PMV's August 31 update reports an interim 46% response rate, 35 of 76 patients, and a 10.0-month median duration of response in an ovarian-cancer cohort. It says enrollment for the primary analysis is complete, a broader Phase 2 pivotal update is planned at a fourth-quarter 2026 medical conference, and a New Drug Application submission for accelerated approval is planned in the first quarter of 2027. The dataset has a May 14, 2026 cutoff, is interim, and comes from a single-arm study. It is evidence about future probability, not approval or revenue. PMV Pharmaceuticals August 31, 2026 interim data update

No candidate clears the Desk's trade-qualified standard. PMVP wins the research screen because its current filing boundary, capital structure, regulatory trigger, and live price are unusually close together. The decision remains Watchlist research; reject for current trade.

Why This Can Move More Than 5% Soon

The offering creates a short-term state ladder:

Delivery and settlement: The securities were priced, but the expected September 2 delivery and cash receipt need confirmation. A priced deal is not a settled deal.
First post-close tape: Once common shares and pre-funded warrants are delivered, the market must discover a new denominator. The common shares and warrants are immediately separable, but the warrants are not listed and may have no public market.
Q4 clinical update: PMV plans to present the primary ovarian analysis and updates from all PYNNACLE Phase 2 pivotal cohorts at a medical conference in the fourth quarter of 2026. The primary analysis could support or undermine the current clinical narrative.
NDA submission: The company plans to submit in Q1 2027. Submission is not acceptance or approval, but the filing itself can affect the warrant reset and the common price.
NDA acceptance and warrant reset: On the date of the initial public announcement of FDA acceptance for review, the common warrant exercise price can be reduced to the greater of 33% of the initial price and the lesser of the then exercise price or a five-day VWAP measured after the announcement. The warrant share count increases so the aggregate exercise price is preserved. If the FDA accepts the NDA, PMV may require cash exercise of up to 50% of the warrants during the 30-to-60-day period after the announcement. PMV Pharmaceuticals September 2, 2026 Form 424B5

The cheapest falsification sequence is delivery and cash receipt, then the actual post-close common denominator, then the first regular-session price and top-of-book audit, then the Q4 data update, and finally the NDA and warrant-reset state. The thesis cannot skip from offering headline to current float.

10/5 Asymmetry Gate

The holding window is September 2 through December 31, 2026, covering the expected offering settlement, the first post-close tape, and the planned fourth-quarter clinical update. The $1.2600 finance-feed mark is a reference observation, not a verified executable entry.

Test	Calculation or evidence	Result
Reference price	$1.2600 at 2026-09-02 15:18:57 UTC; finance-feed observation	Reference only
Favorable base move	Short from $1.2600 to $0.9500: ($1.2600 - $0.9500) / $1.2600	+24.60% before costs
Credible adverse move	Short from $1.2600 to $2.0500: ($2.0500 - $1.2600) / $1.2600	-62.70% before costs
Gross favorable-to-adverse ratio	24.60% / 62.70%	0.39:1, below 2:1
Illustrative public borrow carry	1.2% annualized feed x 120 / 365, only if unchanged	About 0.39% before spread, slippage, recall, and buy-in
Price-only weighted target	25% x $0.7500 + 55% x $0.9500 + 20% x $2.0500	$1.1200
Price-only gross expected short return	($1.2600 - $1.1200) / $1.2600	+11.11% before costs
After-cost value	Delivery, entry, locate, current denominator, warrant state, clinical update, spread, depth, and exit liquidity are incomplete	Cannot compute responsibly
Measurement basis	Verified entry or reference-only	Reference-only
Classification	10/5 downside, economics, and execution gates	Watchlist research; reject for current trade

The base case clears the favorable 10% test, but the adverse case is far above the permitted 5% rise and the gross ratio is only 0.39:1. The weighted target is a price-only map, not a probability-weighted trading EV. The calculation also excludes the possibility that a positive FDA decision increases both the common price and the number of reset warrant shares. I do not have sufficient reliable data to quantify an after-cost EV accurately.

Canonical rubric: Trade-qualified requires a verified executable entry, a favorable base move of at least 10%, a credible adverse rise no greater than 5%, at least 2:1 gross reward to adverse risk, and completed direction-specific execution gates. Watchlist means the research may be useful but the entry, economics, or evidence is incomplete. Reject means the candidate fails the hurdle or lacks a safe trade expression. PMVP is Watchlist research and Reject for current execution.

What Should Surprise the Reader

The offering price is not a floor. It is the price at which a package of common or pre-funded securities and warrants was sold to investors under a particular underwriting agreement. The common share can trade below the package price after delivery, and it can also trade above it if the clinical catalyst dominates. Treating $1.21 as an automatic support level is the same unit-price error as treating it as an automatic short target.

The second surprise is that an issuance can improve cash and worsen per-share pressure at the same time. PMV raised capital to fund a late-stage program and extend runway. The common and pre-funded portion may add approximately 41.955 million common-equivalent shares to a 53.460 million share base. That is a material denominator change, but the actual common shares, pre-funded exercises, holder ownership limits, and post-close count remain separate states.

The third surprise is the regulatory reset. FDA acceptance is usually described as a positive catalyst. Here it can also lower the warrant exercise price, increase warrant shares to preserve aggregate exercise value, and permit a mandatory cash exercise of up to half the warrants in a defined window. That can create future supply, but only after the regulator, issuer, holder, notice, exercise, and settlement states are observed.

The Setup

PMV is a clinical-stage precision-oncology company developing rezatapopt, an oral small molecule intended to correct the p53 Y220C mutation. The short thesis is not that the drug will fail. It is that the current price can be vulnerable if the market treats an underwritten financing as a clean growth reset while ignoring the new denominator and the conditions around its regulatory catalyst.

The state ladder is:

Clinical state: interim 46% ORR in 76 evaluable ovarian-cancer patients, with a May 14 data cutoff, single-arm design, and a planned primary analysis update.
Regulatory state: FDA interaction supports the company's strategy for a future NDA submission; no NDA acceptance or approval has been observed.
Pre-close financing state: The offering is priced and registered. The filing expected delivery on or about September 2 subject to customary conditions.
Settled financing state: Gross proceeds, underwriting discounts, net proceeds, delivered common shares, delivered pre-funded warrants, and common warrants must be confirmed.
Denominator state: 53.460 million common shares were outstanding at June 30, before the new common or pre-funded securities and before any warrant exercise. Options and plan reserves are additional claims.
Warrant state: Common warrants are immediately exercisable at an initial $1.21 price, unlisted, and subject to a later FDA-linked reset and potential mandatory exercise.
Cash state: June 30 financial assets are filed; management's post-offering runway estimate is forward-looking until the cash receipt and next balance sheet are filed.

The market may be pricing the offering as a clean balance-sheet repair and the August 31 data as a de-risked pathway to accelerated approval. The short counter-thesis is that capital structure, regulatory state, and clinical probability remain conditional. Both narratives can be true at once.

The Market Price

Observation	Value	Timestamp / session	Source and limitation
Live finance-feed quote	$1.2600, down $0.0300 or 2.32558%; open $1.2600; high $1.2900; low $1.2450; volume 245,195; market-cap context $67,267,505	Sep. 2, 2026 at 15:18:57 UTC; regular U.S. session	PMVP finance-feed quote; bid, ask, spread, depth, venue, and settlement are not independently verified
Second real-time page	$1.2750, down 1.16%; 50-day moving average $1.24; 200-day moving average $1.27	Sep. 2, 2026 at 11:34 a.m. EDT; market open page	PMVP StockAnalysis statistics; time differs from the finance feed and does not establish an entry
Latest prior-session context	$1.2900 close, $1.2800 pre-market mark at 8:49 a.m. EDT	Sep. 1 close and Sep. 2 pre-market	PMVP StockAnalysis statistics; prior-session context only
Offering reference	$1.2100 per common share and warrant, $1.20999 per pre-funded warrant and warrant; expected delivery on or about Sep. 2	Aug. 31 pricing and Sep. 2 prospectus filing; close subject to conditions	PMVP Form 8-K and PMVP Form 424B5; not a price floor
Current common denominator	53,460,432 shares issued and outstanding at Jun. 30	June 30, 2026 filed state	PMVP Form 10-Q; excludes the new offering
Financial assets and operating cash	$79.431M cash, cash equivalents, and marketable securities; -$34.256M H1 operating cash	June 30, 2026 filed state	PMVP Form 10-Q; post-offering cash is not filed
Public borrow and short interest	1.2% borrow fee, 3.2M shares available; about 2.2M short, 4.2% of shares, 5.9 days to cover	Sep. 1 borrow snapshot and Aug. 14 FINRA settlement	PMVP CurvedTrading context; not an account-level locate
Top of book and exit	Bid, ask, spread, depth, venue quality, volume quality, realistic exit liquidity, delivery, recall, buy-in, and settlement evidence	Current run	I do not have sufficient reliable data to quantify this accurately.

The live quote is close to the package price, but the offering's price, current quote, clinical data, and post-close denominator do not share one completed state. I use $1.2600 as the reference because it is the latest finance-feed observation used in the machine signal. It is not an executable entry.

The Mispricing

The market is being asked to price four different objects:

A company with $79.431 million of financial assets and no product revenue.
A priced financing that may add roughly $47 million of net cash.
A common-equivalent issuance block that is approximately 78.5% of the last-filed common denominator, plus another conditional warrant block of the same size.
A clinical and regulatory path that could support a higher price before the new warrants become current shares.

The inference is that the offering can be misread in either direction. A simplistic bull sees cash and Phase 2 data but ignores the denominator. A simplistic short sees 83.910 million offered or warrant shares and ignores that only the common or pre-funded portion is initially deliverable, the warrants are conditional claims, the net proceeds extend runway, and the clinical data can produce a squeeze. The best current research question is whether the first post-close market price is accepted after the securities settle and the claim ledger is reconciled.

Why the market may be right:

The offering was priced at a modest discount to the current quote and was described as oversubscribed in the company release.
The proceeds can extend the operating runway into the first quarter of 2028 under management's current plan.
The ovarian cohort has a reported 46% response rate and 10.0-month median duration of response, although the analysis is interim and single-arm.
FDA feedback supports the company's stated plan to submit an NDA in the first quarter of 2027.
The stock has a large Nasdaq market and public borrow availability relative to the current short-interest figure.

The load-bearing assumption for the short is that the new denominator and warrant overhang matter sooner than the cash and clinical catalysts. That assumption is fragile. If delivery is clean, cash arrives, the Q4 data improve the regulatory probability, and the common holds above the offering package, the short thesis loses its timing edge.

The Positioning

Public positioning is modest and does not authorize a trade:

CurvedTrading reports a 1.2% public borrow fee and approximately 3.2 million shares available on September 1.
It reports approximately 2.2 million shares short, 4.2% of shares outstanding, and 5.9 days to cover at the August 14 settlement.
StockAnalysis shows similar short interest of 2.24 million, 4.20% of outstanding shares, 4.84% of float, and 6.61 days to cover, but these are delayed and denominator-dependent.
The public data do not identify the financing investors' hedge behavior, the first resale, the current utilization, account-level locate, recall, buy-in, or settlement terms.

Positioning score: 3/5. The stock is borrowable in public feeds and does not look crowded by short interest alone. That lowers squeeze pressure from existing shorts but does not remove clinical or financing-driven demand. The Desk blocks execution because the short-side gates are incomplete.

The Catalyst

State	Timing	What would confirm it	Short-side implication
Offering delivery	On or about Sep. 2, 2026	Transfer of common shares or pre-funded warrants, common warrants, and cash receipt	A clean settlement can increase supply and change the denominator; a failed or delayed close changes the thesis
First post-close market acceptance	First regular sessions after settlement	Current common count, bid, ask, spread, depth, venue, volume quality, and exit liquidity	Persistent trade below the package may support the short; durable acceptance above it is a warning
Q4 PYNNACLE update	Fourth quarter of 2026	Primary ovarian analysis and updates from all pivotal cohorts with stated cutoff and endpoints	Better data can overwhelm the supply thesis; a weak or delayed update can pressure price
NDA submission	First quarter of 2027	Filed NDA and stated indication, data package, and review path	Submission is not acceptance or approval, but it can trigger a repricing
FDA NDA acceptance	After the planned submission	FDA acceptance announcement and warrant-reset calculation	Positive acceptance can support price, reset the warrant exercise price, and increase warrant shares
Warrant exercise and settlement	30 to 60 days after positive NDA acceptance if required	Company notice, holder exercise, cash received, settled shares, and revised denominator	Future supply may rise, but a positive clinical event can create the squeeze before exercise

The cheapest disconfirming observation is the first settlement and share-count filing. It tells the Desk whether the common-equivalent block arrived, whether cash was received, and whether the market is treating the new securities as supply, runway, or both.

The Payoff

The scenario probabilities are judgmental underwriting inputs, not market-implied odds. They sum to 100%.

Case	Price target	Probability	Short interpretation
Top case	$0.7500	25%	Settlement is complete, the new denominator is accepted, the clinical update does not improve the approval path, and the quote reprices below the financing package
Base case	$0.9500	55%	The offering adds conditional supply and cash, but the market waits for the Q4 update while the quote drifts below the package after costs and dilution are understood
Bottom case	$2.0500	20%	The new cash removes near-term funding risk and the interim or Q4 data increase the probability of an NDA path, producing a squeeze before any warrant reset supply arrives

Price-only weighted target: $1.1200. Price-only reference return for a short from $1.2600: 11.11% before costs. This cannot be treated as actionable EV because delivery, cash receipt, current denominator, first resale, warrant state, spread, borrow, locate, and exit liquidity are not verified. The bottom case is a protection test against a positive clinical and regulatory repricing, not a claim that $2.05 is fair value.

The Kill Shot

The strongest counterparty argument is that PMV has solved the immediate financing problem. The company reports nearly $79.4 million of financial assets at June 30, expects roughly $47 million of net offering proceeds, and says the combined resources fund the program into Q1 2028. The offering was priced with a common warrant, which can attract investors who want both clinical exposure and embedded upside. The August 31 data update reported a 46% response rate and 10-month median response duration, with FDA feedback supporting a future accelerated-approval filing. If the first primary analysis is stronger than the May 14 interim cutoff, a $2.05 rebound is not an extreme scenario.

That argument rejects the short today. It does not erase the conditional supply block. It means the timing of dilution, the quality of the Q4 update, and the regulatory probability must be observed in order. An investor cannot claim that 41.955 million pre-funded or common-equivalent shares are current float, and a short seller cannot claim that the offering price is a guaranteed ceiling.

What Could Go Wrong

The offering closes cleanly, the net proceeds arrive, and the new denominator is accepted without an immediate price break.
The Q4 primary analysis improves confidence in accelerated approval.
FDA acceptance of the NDA becomes a positive catalyst before any warrant exercise.
The company uses the new cash efficiently and the market values runway more than dilution.
Underwriters or offering investors retain securities rather than selling into the first tape.
The common and pre-funded securities are delivered, but the stock rises because the offering removed a financing overhang.
The current quote is already below an economic cash-per-share reference after settlement, making a short a poor value trade.
A halt, clinical headline, regulatory response, recall, buy-in, or settlement delay produces a gap beyond a nominal price control.
The public borrow rate and availability do not match a broker's account-level locate or change before exit.
Common warrants reset after FDA acceptance, increasing the future warrant share count while the common price rises.
The May 14 clinical cutoff or single-arm design fails to generalize to the final analysis.
The company delays the NDA, changes the indication, or receives regulatory feedback that invalidates the expected timetable.

What Would Prove This Wrong

The offering closes and the current filing shows no material increase in common or pre-funded shares, no cash receipt, or no accessible resale path.
The first post-close regular sessions show durable price acceptance above $1.35 with verified bid, ask, spread, depth, venue quality, volume quality, and exit liquidity.
The Q4 data update materially improves the clinical probability, includes a robust primary analysis, or adds a regulatory designation that supports a higher common value.
The next filing shows post-offering cash, operating cash, current claims, options, pre-funded exercises, common warrants, and shares in one auditable bridge.
A positive NDA acceptance announcement triggers a warrant reset and the common trades higher despite the future supply claim.
Any required quote, spread, depth, venue, volume-quality, exit-liquidity, locate, borrow, recall, buy-in, settlement, or current-denominator check fails. In that case the correct action is to keep entry.price null and execution.can_execute false, not to force a price stop.

Risk Audit

Risk	Why it matters	Control
Clinical squeeze	Interim single-arm data and FDA progress can reprice the common before future supply arrives	Treat $2.05 as a real adverse case; do not short without a current catalyst and borrow audit
Financing state	A priced offering may not yet be delivered or settled; a delay can create a different tape	Require delivery, cash receipt, securities issued, and the post-close denominator
Warrant reset	FDA acceptance can lower the exercise price and increase warrant shares while also supporting the common price	Model the reset as a two-sided catalyst; verify notice, formula, exercise, and settlement
Cash runway	$79.431M existing financial assets plus estimated $47M net proceeds can remove near-term financing pressure	Reconcile the first post-close balance sheet and operating-cash path
Price reference	$1.21 is an offering package reference, not a floor or ceiling	Do not use the financing price as entry, stop, or liquidation value
Borrow and recall	Public 1.2% fee and 3.2M availability are not an account-level locate	Verify broker locate, actual fee, utilization, recall, buy-in, and settlement terms
Liquidity	245K shares of live volume may be event-driven and may not survive the exit	Verify bid, ask, spread, depth, venue quality, volume quality, and realistic exit
Denominator	Current common shares exclude the new common, pre-funded, warrant, option, and plan states	Require one current filed denominator before any per-share arithmetic
Carry	Borrow is low in the public feed, but the holding window includes a clinical event and may extend	Model actual fee, slippage, gap, and time-to-event; abandon if economics deteriorate

Best Trade Strategy

Instrument: Unlevered PMVP common stock only if every gate passes. No options, leverage, margin, market orders, or no-locate short.
Entry: No executable entry now. The $1.2600 observation is reference-only. entry.price remains null until offering delivery, cash receipt, current common denominator, current warrant and pre-funded state, fresh regular-session quote, top-of-book, broker-level locate, borrow and recall terms, and realistic exit liquidity are verified.
Targets: Reference-only top $0.7500, base $0.9500, bottom $2.0500, with probabilities 25%, 55%, and 20%.
Invalidation: Remove the thesis if the first post-close filing shows no material supply, if cash and clinical evidence materially improve the common value, if the Q4 data or NDA path raises the approval probability, or if any short-side execution gate fails.
Horizon: September 2 through December 31, 2026, with re-underwriting after settlement, the first regular sessions, the Q4 clinical update, any FDA communication, and every share-count or cash filing.
Do not trade: Do not short because $1.21 is the offering price, because warrant shares exist, because the company has no revenue, or because public borrow is available. Do not treat registered or exercisable claims as current float before delivery and settlement.
Monitor: Offering closing and cash receipt; current common and pre-funded shares; warrant reset terms; first resale; Q4 data and cutoff; FDA submission or acceptance; live bid, ask, spread, depth, venue, borrow, recall, and exit.

Sources

PMV Pharmaceuticals August 31, 2026 Form 8-K - offering terms, expected September 2 close, warrant reset, potential mandatory exercise, estimated net proceeds, and use of proceeds.
PMV Pharmaceuticals September 2, 2026 Form 424B5 - final offering amounts, $1.21 package price, underwriting discounts, delivery, common denominator, warrant terms, reset mechanics, and use of proceeds.
PMV Pharmaceuticals August 31, 2026 clinical data Form 8-K exhibit - 46% ORR, 76 evaluable patients, 10.0-month median response duration, Q4 data plan, and Q1 2027 NDA plan.
PMV Pharmaceuticals June 30, 2026 Form 10-Q - financial assets, operating cash use, no product revenue, going-concern language, current common shares, ATM capacity, and clinical funding needs.
PMVP finance-feed quote - live price, change, open, high, low, volume, and market-cap context at 2026-09-02 15:18:57 UTC.
PMVP StockAnalysis statistics - a second time-stamped quote, shares, market cap, short interest, cash, and price statistics.
PMVP CurvedTrading borrow and short-interest context - public borrow fee, availability, dated short interest, and days-to-cover context; not an account-level locate.
KALA BIO August 27, 2026 Form 8-K - ranked candidate Nasdaq deficiency and appeal state.
KALA BIO June 30, 2026 Form 10-Q - ranked candidate cash, operating cash use, financing, note receivable, and denominator context.
KALA Short Interest Tracker - ranked candidate public borrow, availability, and dated short-interest context.
LivePerson August 20, 2026 vote update - ranked candidate adjournment, vote count, and merger state.
LivePerson June 30, 2026 Form 10-Q - ranked candidate revenue, cash, merger consideration, and debt context.
Nasdaq LivePerson Corporate Action Alert - ranked candidate anticipated last trading date, suspension date, and tentative closing path.
LPSN finance-feed quote - ranked candidate live price, range, volume, and market-cap context.
LPSN CurvedTrading borrow and short-interest context - ranked candidate public borrow and short-interest context.

Research Quality Scorecard

Criterion	Score	Reason
Market disagreement	4/5	The offering creates a large conditional supply block, but the cash injection and clinical path make a simple dilution conclusion incomplete
Evidence base	5/5	Two fresh primary financing filings, a fresh clinical filing, the June 10-Q, live price context, and public positioning data are paired
Positioning and flows	3/5	Borrow and short interest are public, but account-level locate, current utilization, investor hedging, first resale, and exit data are missing
Catalyst path	4/5	Delivery, first post-close tape, Q4 data, NDA submission, and FDA acceptance are observable, but several are future states
Payoff architecture	2/5	The base decline clears 10%, but the adverse rise is far above 5% and the gross ratio is 0.39:1
Invalidation discipline	4/5	Settlement, denominator, clinical, regulatory, cash, and execution invalidation tests are explicit
Differentiated insight	5/5	Separates common and pre-funded delivery, warrant claims, FDA-linked reset, cash runway, clinical probability, and offering-price anchoring
Client value	4/5	The state ladder explains why a large offering is not automatically a short, but execution evidence is incomplete

Total: 31/40. Classification: Watchlist research; Reject for current execution. The score cannot override the failed 10/5 adverse bound, null entry, unverified settlement and denominator, and missing broker-level execution evidence.

Bottom Line

PMVP is the best new U.S. short research opportunity in this run because a fresh underwritten offering, a moving common denominator, and an FDA-linked warrant reset are being adjudicated against a current quote today. The short-side observation is concrete: the common and pre-funded portion equals roughly 78.5% of the last-filed common denominator, and the accompanying warrants add a second conditional block of the same size.

That is not enough to authorize a short. The company also has $79.431 million of financial assets, expects about $47 million of net offering proceeds, reports promising interim data, and plans a Q4 data update and Q1 2027 NDA submission. Those facts make a sharp adverse squeeze credible. The price-only map produces an attractive 11.11% reference return, but the base-to-adverse ratio is 0.39:1 before costs. Keep entry.price null and execution.can_execute false. Re-underwrite after settlement, the actual denominator, the first post-close tape, and the next clinical result.

AI Illustration Prompt

Create a realistic editorial illustration for The Mispricing Desk about PMV Pharmaceuticals (PMVP) on the day of a $50.765M gross underwritten offering: a sober institutional oncology-finance room with a central settlement desk divided into three clearly separated ledgers. On the first ledger, show JUN 30 COMMON 53.460M, OFFERING COMMON 22.055M OR PRE-FUNDED 19.900M, COMMON WARRANTS 41.955M, and a large red stamp DELIVERY AND SETTLEMENT PENDING. On the second ledger, show $79.431M FINANCIAL ASSETS, H1 OPERATING CASH -$34.256M, NO PRODUCT REVENUE, SUBSTANTIAL DOUBT, and a blue incoming wire labeled ESTIMATED NET PROCEEDS ~$47M, with the annotation CASH RECEIPT NOT YET FILED. On the third ledger, show a clinical trial board reading PYNNACLE PHASE 2 / 76 EVALUABLE / 46% ORR / 10.0M MEDIAN RESPONSE, a separate note MAY 14 DATA CUTOFF / SINGLE ARM / INTERIM, and a calendar marked Q4 2026 PRIMARY UPDATE / Q1 2027 NDA PLAN. Above the desk, draw an FDA decision panel reading NDA ACCEPTANCE ANNOUNCEMENT, connected to a mechanical warrant calculator with INITIAL WARRANT PRICE $1.21, RESET FLOOR 33% OF INITIAL, 5-DAY VWAP, SHARE COUNT INCREASE TO PRESERVE AGGREGATE EXERCISE VALUE, and UP TO 50% CASH MANDATORY EXERCISE 30-60 DAYS AFTER POSITIVE ACCEPTANCE. On a market monitor, show two time-stamped quote cards: $1.2600 / -2.33% / 245,195 VOL / 15:18:57 UTC and $1.2750 / 11:34 AM EDT, connected by a thin amber line labeled QUOTE WINDOW, NOT ONE PRICE STATE. Put a restrained price path diagram on the wall with TOP $0.75 / 25%, BASE $0.95 / 55%, and BOTTOM $2.05 / 20%, where the bottom branch rises toward the FDA panel as a squeeze path, not downward. Add a small borrow panel reading PUBLIC BORROW 1.2% / 3.2M AVAILABLE / 2.2M SHORT / 5.9 DTC, with a red stamp BROKER LOCATE, RESALE, DEPTH, EXIT UNVERIFIED. Make the distinction between settled common, pre-funded claims, future warrants, cash runway, clinical probability, FDA acceptance, and current float visually unmistakable. Use charcoal, warm paper, clinical teal, regulatory blue, brushed aluminum, muted amber, and one controlled red accent; documentary financial-journalism lighting; tactile paper, glass, steel, and matte display textures; no rockets, coins, generic candlestick charts, hype imagery, invented logos, or personalized advice. Add a subtle readable The Mispricing Desk watermark. Wide 16:9 composition, premium magazine art direction, precise typography, sober, tense, and unresolved.